BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22391922)

  • 1. Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents.
    Galassi R; Burini A; Ricci S; Pellei M; Rigobello MP; Citta A; Dolmella A; Gandin V; Marzano C
    Dalton Trans; 2012 May; 41(17):5307-18. PubMed ID: 22391922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer.
    Gambini V; Tilio M; Maina EW; Andreani C; Bartolacci C; Wang J; Iezzi M; Ferraro S; Ramadori AT; Simon OC; Pucciarelli S; Wu G; Dou QP; Marchini C; Galassi R; Amici A
    Eur J Med Chem; 2018 Jul; 155():418-427. PubMed ID: 29906688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study on the inhibition of dihydrofolate reductase (DHFR) from Escherichia coli by gold(i) phosphane compounds. X-ray crystal structures of (4,5-dichloro-1H-imidazolate-1-yl)-triphenylphosphane-gold(i) and (4,5-dicyano-1H-imidazolate-1-yl)-triphenylphosphane-gold(i).
    Galassi R; Oumarou CS; Burini A; Dolmella A; Micozzi D; Vincenzetti S; Pucciarelli S
    Dalton Trans; 2015 Feb; 44(7):3043-56. PubMed ID: 25567238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gold(I) thiotetrazolates as thioredoxin reductase inhibitors and antiproliferative agents.
    Serebryanskaya TV; Lyakhov AS; Ivashkevich LS; Schur J; Frias C; Prokop A; Ott I
    Dalton Trans; 2015 Jan; 44(3):1161-9. PubMed ID: 25413270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkynyl gold(I) phosphane complexes: Evaluation of structure-activity-relationships for the phosphane ligands, effects on key signaling proteins and preliminary in-vivo studies with a nanoformulated complex.
    Andermark V; Göke K; Kokoschka M; Abu El Maaty MA; Lum CT; Zou T; Sun RW; Aguiló E; Oehninger L; Rodríguez L; Bunjes H; Wölfl S; Che CM; Ott I
    J Inorg Biochem; 2016 Jul; 160():140-8. PubMed ID: 26850306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the C^N^C theme: Synthesis and biological properties of tridentate cyclometalated gold(III) complexes.
    Jürgens S; Scalcon V; Estrada-Ortiz N; Folda A; Tonolo F; Jandl C; Browne DL; Rigobello MP; Kühn FE; Casini A
    Bioorg Med Chem; 2017 Oct; 25(20):5452-5460. PubMed ID: 28823538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luminescent alkynyl-gold(I) coumarin derivatives and their biological activity.
    Arcau J; Andermark V; Aguiló E; Gandioso A; Moro A; Cetina M; Lima JC; Rissanen K; Ott I; Rodríguez L
    Dalton Trans; 2014 Mar; 43(11):4426-36. PubMed ID: 24302256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases.
    Urig S; Fritz-Wolf K; Réau R; Herold-Mende C; Tóth K; Davioud-Charvet E; Becker K
    Angew Chem Int Ed Engl; 2006 Mar; 45(12):1881-6. PubMed ID: 16493712
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
    Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
    Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gold(i) and gold(iii) phosphine complexes: synthesis, anticancer activities towards 2D and 3D cancer models, and apoptosis inducing properties.
    Srinivasa Reddy T; Privér SH; Rao VV; Mirzadeh N; Bhargava SK
    Dalton Trans; 2018 Nov; 47(43):15312-15323. PubMed ID: 30187047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the antitumoral activity of phosphine-thiosemicarbazone gold(I) complexes obtained by different methodologies.
    González-Barcia LM; Fernández-Fariña S; Rodríguez-Silva L; Bermejo MR; González-Noya AM; Pedrido R
    J Inorg Biochem; 2020 Feb; 203():110931. PubMed ID: 31786438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gold(I) complexes of water-soluble diphos-type ligands: synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition.
    Wetzel C; Kunz PC; Kassack MU; Hamacher A; Böhler P; Watjen W; Ott I; Rubbiani R; Spingler B
    Dalton Trans; 2011 Sep; 40(36):9212-20. PubMed ID: 21826354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazole-based phosphane gold(I) complexes as potential agents for cancer treatment: synthesis, structural studies and antitumour activity.
    Kunz PC; Kassack MU; Hamacher A; Spingler B
    Dalton Trans; 2009 Oct; (37):7741-7. PubMed ID: 19759948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Hydrophilic Gold(I) N-Heterocyclic Carbene (NHC) Complexes as Potent TrxR Inhibitors Using Biochemical and Mass Spectrometric Approaches.
    Karaca Ö; Scalcon V; Meier-Menches SM; Bonsignore R; Brouwer JMJL; Tonolo F; Folda A; Rigobello MP; Kühn FE; Casini A
    Inorg Chem; 2017 Nov; 56(22):14237-14250. PubMed ID: 29095609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents.
    Liu W; Bensdorf K; Proetto M; Abram U; Hagenbach A; Gust R
    J Med Chem; 2011 Dec; 54(24):8605-15. PubMed ID: 22091836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization, and antitumor activity of unusual pseudo five coordinate gold(III) complexes: distinct cytotoxic mechanism or expensive ligand delivery systems?
    Olsen PM; Ruiz C; Lussier D; Le BK; Angel N; Smith M; Hwang CB; Khatib R; Jenkins J; Adams K; Getcher J; Tham F; Chen ZG; Wilson EH; Eichler JF
    J Inorg Biochem; 2014 Dec; 141():121-131. PubMed ID: 25243390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cobaltoceniumethynyl gold(I) as an unusual heterodinuclear bioorganometallic fragment to study the biological properties of alkynyl gold complexes.
    Vanicek S; Kopacka H; Wurst K; Vergeiner S; Kankowski S; Schur J; Bildstein B; Ott I
    Dalton Trans; 2016 Jan; 45(4):1345-8. PubMed ID: 26732365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands.
    Vergara E; Casini A; Sorrentino F; Zava O; Cerrada E; Rigobello MP; Bindoli A; Laguna M; Dyson PJ
    ChemMedChem; 2010 Jan; 5(1):96-102. PubMed ID: 19937669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer cyclometalated [Au(III)m(C(wedge)N(wedge)C)mL]n+ compounds: Synthesis and cytotoxic properties.
    Li CK; Sun RW; Kui SC; Zhu N; Che CM
    Chemistry; 2006 Jul; 12(20):5253-66. PubMed ID: 16642532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New cyclometalated gold (III) complex targeting thioredoxin reductase: exploring as cytotoxic agents and mechanistic insights.
    Abyar F; Tabrizi L
    Biometals; 2020 Jun; 33(2-3):107-122. PubMed ID: 32246384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.